Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected Patients
Background: Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)–infected patients, and adequate immunogenicity and safety are of concern in this population. Methods: In the Swiss HIV Cohort Study, we identified 102 patients who received 17DV while they were HIV infected. We analyzed neutralization titers (NTs) after 17DV administration using the plaque reduction neutralization test. NTs of 1:10 were defined as reactive, and those of 1:
Dateien zu dieser Publikation
Keine Lizenzangabe